No Data
No Data
Chimeric Therapeutics Appoints COO; Shares Rise 4%
Chimeric Therapeutics (ASX:CHM) appointed Rebecca McQualter as its chief operating officer, the clinical stage cell therapy company said Thursday. McQualter has previously worked at companies such as
Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20%
Chimeric Therapeutics (ASX:CHM) said Jennifer Chow has given notice of her resignation as the company's chief executive officer and managing director, effective May 24, according to a Wednesday filing
Chimeric Therapeutics Obtains Patent Application Covering CORE-NK Technology; Shares Up 3%
Chimeric Therapeutics (ASX:CHM) said that the US Patent & Trademark Office has allowed for issuance of a patent application covering the CORE-NK platform technology for blood cancers and solid tumors,
Chimeric Therapeutics Highlights Key Cell Therapy Targets in Treatment of Various Cancers
Chimeric Therapeutics (ASX: CHM) has reported strong progress for the 12 months to end December and highlighted key cell therapy targets for the coming year.
Stocks of the Hour: PainChek, Chimeric Therapeutics, Torque Metals
To register for Friday's webinar click here.PainChek (ASX:PCK), developer of the world's first smart based pain assessment and monitoring application, has announced it has established a reseller agree
Chimeric Therapeutics Treats First Patient in Phase 1B Leukemia Trial
Chimeric Therapeutics (ASX:CHM) treated the first patient in its phase 1b clinical trial investigating the use of the cell therapy CHM201 in combination with standard-of-care medication azacitidine an
No Data